|75.32||+0.0800||+0.11%||Vol 82.77K||1Y Perf -32.68%|
|Mar 24th, 2023 12:03 DELAYED|
|1.55 2.06%||- -|
|Target Price||77.83||Analyst Rating||Hold 3.17|
|Potential %||3.87||Finscreener Ranking||+ 37.65|
|Insiders Trans % 3/6/12 mo.||-/-33/-75||Value Ranking||★★ 45.28|
|Insiders Value % 3/6/12 mo.||75/67/-74||Growth Ranking||★★ 45.19|
|Insiders Shares Cnt. % 3/6/12 mo.||79/74/-60||Income Ranking||— -|
|Price Range Ratio 52W %||16.87||Earnings Rating||Strong Sell|
|Market Cap||6.81B||Earnings Date||4th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||1.08|
|EPS Growth Next 5 Years %||8.40|
|Avg. Weekly Volume||741.11K|
|Avg. Monthly Volume||755.10K|
|Avg. Quarterly Volume||662.15K|
DaVita Inc. (NYSE: DVA) stock closed at 75.24 per share at the end of the most recent trading day (a -1.97% change compared to the prior day closing price) with a volume of 506.11K shares and market capitalization of 6.81B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 67000 people. DaVita Inc. CEO is Javier J. Rodriguez.
The one-year performance of DaVita Inc. stock is -32.68%, while year-to-date (YTD) performance is 0.76%. DVA stock has a five-year performance of 15.75%. Its 52-week range is between 65.28 and 124.81, which gives DVA stock a 52-week price range ratio of 16.87%
DaVita Inc. currently has a PE ratio of 11.80, a price-to-book (PB) ratio of 13.71, a price-to-sale (PS) ratio of 0.82, a price to cashflow ratio of 4.60, a PEG ratio of 2.32, a ROA of 4.26%, a ROC of 7.31% and a ROE of 90.25%. The company’s profit margin is 7.54%, its EBITDA margin is 18.70%, and its revenue ttm is $8.69 Billion , which makes it $96.48 revenue per share.
Of the last four earnings reports from DaVita Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.08 for the next earnings report. DaVita Inc.’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for DaVita Inc. is Hold (3.17), with a target price of $77.83, which is +3.87% compared to the current price. The earnings rating for DaVita Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DaVita Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DaVita Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 2.22, CCI20 : -83.75, Chaikin Money Flow : 0.01, MACD : -1.33, Money Flow Index : 40.41, ROC : -4.58, RSI : 38.36, STOCH (14,3) : 22.36, STOCH RSI : 0.11, UO : 44.85, Williams %R : -77.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DaVita Inc. in the last 12-months were: Barbara J. Desoer (Option Excercise at a value of $474 968), Barbara J. Desoer (Sold 2 320 shares of value $226 010 ), Charles G. Berg (Option Excercise at a value of $712 418), Charles G. Berg (Sold 2 166 shares of value $167 622 ), James O. Hearty (Option Excercise at a value of $149 491), Javier J. Rodriguez (Option Excercise at a value of $5 232 441), John M. Nehra (Buy at a value of $355 675), Kathleen Alyce Waters (Option Excercise at a value of $2 740 860), Michael David Staffieri (Buy at a value of $1 554 000)
|Analyst Ratings||Current||1 M ago||3 M ago|
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
CEO: Javier J. Rodriguez
Telephone: +1 720 631-2100
Address: 2000 16th Street, Denver 80202, CO, US
Number of employees: 67 000
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.